Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2023

Open Access 01-12-2023 | Fibromatosis | Case report

Papillary thyroid carcinoma with fibromatosis-like stroma: a case report and review of the literature

Authors: Antonio Toniato, Marco Brusoni, Marica Mirabella, Luca Pomba, Vasileios Mourmouras, Antonio Scapinello, Enrico Battistella

Published in: BMC Endocrine Disorders | Issue 1/2023

Login to get access

Abstract

Background

Papillary thyroid carcinoma (PTC) is a common neoplasia with multiple variants. One of these extremely rare and poorly described variants is PTC with fibromatosis-like stroma (PTC-FMS), a peculiar entity distinguished by its predominant mesenchymal component. This paper reviews the literature, discusses the diagnostic challenges, and the clinical and surgical implications of this type of tumor which has fewer than 30 cases reported in the literature.

Case presentation

We reported a case of PTC-FMS found in a 41-year-old Italian woman, who came to our Institute with a recent growth in the form of a mass on the neck. Further immunohistochemical examination showed β-catenin aberrant staining both in the nuclei and cytoplasm of the mesenchymal cells. The patient underwent total thyroidectomy and received radioactive iodine (RAI) 2 months after surgery.

Conclusion

Given the possibility of recurrence of PTC-FMS and the ineffectiveness of RAI therapy, complete surgical resection represents the main treatment for this type of tumor. Despite the fact that the specific nature of these lesions has yet to be determined, guidelines for classical PTC should be followed.
Literature
1.
go back to reference DeLellis RA. Pathology and genetics of tumours of endocrine organs. Vol. 8. IARC; 2004. DeLellis RA. Pathology and genetics of tumours of endocrine organs. Vol. 8. IARC; 2004.
2.
go back to reference Toniato A, Boschin I, Casara D, Mazzarotto R, Rubello D, Pelizzo M. Papillary thyroid carcinoma: factors influencing recurrence and survival. Ann Surg Oncol. 2008;15:1518–22.CrossRefPubMed Toniato A, Boschin I, Casara D, Mazzarotto R, Rubello D, Pelizzo M. Papillary thyroid carcinoma: factors influencing recurrence and survival. Ann Surg Oncol. 2008;15:1518–22.CrossRefPubMed
3.
go back to reference Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, ..., Mete O. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol 2022;33(1):27–63. Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, ..., Mete O. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol 2022;33(1):27–63.
4.
go back to reference Rebecchini C, Nobile A, Piana S, Sarro R, Bisig B, Gerasimos SP, et al. Papillary thyroid carcinoma with nodular fasciitis-like stroma and β-catenin mutations should be renamed papillary thyroid carcinoma with desmoid-type fibromatosis. Mod Pathol. 2017;30:236–45.CrossRefPubMed Rebecchini C, Nobile A, Piana S, Sarro R, Bisig B, Gerasimos SP, et al. Papillary thyroid carcinoma with nodular fasciitis-like stroma and β-catenin mutations should be renamed papillary thyroid carcinoma with desmoid-type fibromatosis. Mod Pathol. 2017;30:236–45.CrossRefPubMed
5.
go back to reference Nardi F, Basolo F, Crescenzi A, Fadda G, Frasoldati A, Orlandi F, et al. Italian consensus for the classification and reporting of thyroid cytology. J Endocrinol Invest. 2014;37:593–9.CrossRefPubMed Nardi F, Basolo F, Crescenzi A, Fadda G, Frasoldati A, Orlandi F, et al. Italian consensus for the classification and reporting of thyroid cytology. J Endocrinol Invest. 2014;37:593–9.CrossRefPubMed
6.
go back to reference Ginter PS, Scognamiglio T. Papillary thyroid carcinoma with nodular fasciitis-like stroma: a usual entity with distinctive morphology. Int J Surg Pathol. 2015;23:305–7.CrossRefPubMed Ginter PS, Scognamiglio T. Papillary thyroid carcinoma with nodular fasciitis-like stroma: a usual entity with distinctive morphology. Int J Surg Pathol. 2015;23:305–7.CrossRefPubMed
7.
go back to reference Ostrowski M, Mofflat F, Asa S. Myxomatous change in papillary cacinoma of thyroid. Surg Pathol. 1989;2:249–56. Ostrowski M, Mofflat F, Asa S. Myxomatous change in papillary cacinoma of thyroid. Surg Pathol. 1989;2:249–56.
8.
go back to reference Chan JKC, Carcangiu ML, Rosai J. Papillary carcinoma of thyroid with exuberant nodular fasciitis-like stroma. Report of three cases. Am J Clin Pathol. 1991;95:309–14.CrossRefPubMed Chan JKC, Carcangiu ML, Rosai J. Papillary carcinoma of thyroid with exuberant nodular fasciitis-like stroma. Report of three cases. Am J Clin Pathol. 1991;95:309–14.CrossRefPubMed
9.
go back to reference Roukain A, la Rosa S, Bongiovanni M, Lalonde MN, Cristina V, Montemurro M, et al. Papillary thyroid carcinoma with desmoid-type fibromatosis: review of published cases. Cancers. 2021;13:4482.CrossRefPubMedPubMedCentral Roukain A, la Rosa S, Bongiovanni M, Lalonde MN, Cristina V, Montemurro M, et al. Papillary thyroid carcinoma with desmoid-type fibromatosis: review of published cases. Cancers. 2021;13:4482.CrossRefPubMedPubMedCentral
10.
go back to reference Mizukami Y, Nomura A, Matsubara F, Michigishi T, Ohmura K, Hashimoto T. Papillary carcinoma of the thyroid gland with fibromatosis-like stroma. Histopathology. 1992;20:355–7.CrossRefPubMed Mizukami Y, Nomura A, Matsubara F, Michigishi T, Ohmura K, Hashimoto T. Papillary carcinoma of the thyroid gland with fibromatosis-like stroma. Histopathology. 1992;20:355–7.CrossRefPubMed
11.
go back to reference Wu Z, Chu X, Fan S, Meng X, Xu C. Papillary thyroid carcinoma with fibromatosis-like stroma: a case report and review of the literature. Oncol Lett. 2012;5:215–7.CrossRefPubMedPubMedCentral Wu Z, Chu X, Fan S, Meng X, Xu C. Papillary thyroid carcinoma with fibromatosis-like stroma: a case report and review of the literature. Oncol Lett. 2012;5:215–7.CrossRefPubMedPubMedCentral
12.
go back to reference Takada N, Mussazhanova Z, Hirokawa M, Nakashima M, Miyauchi A. Immunohistochemical and molecular analyses focusing on mesenchymal cells in papillary thyroid carcinoma with desmoid-type fibromatosis. Pathobiology. 2018;85:300–3.CrossRefPubMed Takada N, Mussazhanova Z, Hirokawa M, Nakashima M, Miyauchi A. Immunohistochemical and molecular analyses focusing on mesenchymal cells in papillary thyroid carcinoma with desmoid-type fibromatosis. Pathobiology. 2018;85:300–3.CrossRefPubMed
13.
go back to reference Suster D, Michal M, Nishino M, Piana S, Bongiovanni M, Blatnik O, et al. Papillary thyroid carcinoma with prominent myofibroblastic stromal component: clinicopathologic, immunohistochemical and next-generation sequencing study of seven cases. Mod Pathol. 2020;33:1702–11.CrossRefPubMed Suster D, Michal M, Nishino M, Piana S, Bongiovanni M, Blatnik O, et al. Papillary thyroid carcinoma with prominent myofibroblastic stromal component: clinicopathologic, immunohistochemical and next-generation sequencing study of seven cases. Mod Pathol. 2020;33:1702–11.CrossRefPubMed
14.
go back to reference Ji YL, Shin JH, Han BK, Eun YK, Seok SK, Ji YK, et al. Diffuse sclerosing variant of papillary carcinoma of the thyroid: Imaging and cytologic findings. Thyroid. 2007;17:567–73.CrossRef Ji YL, Shin JH, Han BK, Eun YK, Seok SK, Ji YK, et al. Diffuse sclerosing variant of papillary carcinoma of the thyroid: Imaging and cytologic findings. Thyroid. 2007;17:567–73.CrossRef
Metadata
Title
Papillary thyroid carcinoma with fibromatosis-like stroma: a case report and review of the literature
Authors
Antonio Toniato
Marco Brusoni
Marica Mirabella
Luca Pomba
Vasileios Mourmouras
Antonio Scapinello
Enrico Battistella
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2023
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-023-01337-y

Other articles of this Issue 1/2023

BMC Endocrine Disorders 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine